Blogger's Note: full access, free subscription
"While consideration of
chemoprevention with PARP inhibitors is on the horizon, many knowledge
gaps exist regarding these agents. Although the trials in EOC provided
some answers regarding the activity of PARP inhibitors, they raised many
other questions. These questions may actually complicate the picture as
newer agents in this drug class make their way to the clinical arena. A
collaborative approach among the researchers is needed to
systematically answer these questions so we are better equipped to
provide effective treatment to the
BRCA-deficient patients. It
is noteworthy that The Cancer Genome Atlas Group analysis did reveal
other commonly deregulated pathways in this disease—such as RB,
RAS/PI3K, FOXM1, and NOTCH—that might provide future opportunities for
therapeutic targeting while the story of the PARP inhibitors continues
to unfold."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.